Business
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress following its launch as a public company.
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress following its launch as a public company.","length":455,"tagName":"p"},{"type":"image","alt":"Atrium Therapeutics logo (PRNewsfoto/Atrium Therapeutics)","displaySize":"","headline":null,"caption":"Atrium Therapeutics logo (PRNewsfoto/Atrium Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":91,"url":"https://media.zenfs.com/en/prnewswire.com/c67ee4110f60781cc28ced8f624c03f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4WWwZ0HIJtR3LRi7nP.vsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2MA--/https://media.zenfs.com/en/prnewswire.com/c67ee4110f60781cc28ced8f624c03f6","width":400,"height":91},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/BoEsxQWkEdTvW9KMWBFm.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE0Ng--/https://media.zenfs.com/en/prnewswire.com/c67ee4110f60781cc28ced8f624c03f6","width":400,"height":91}},"href":"https://mma.prnewswire.com/media/2921796/ATRIUM_Logo_RGB_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Our focused pipeline, strong cash balance and experienced team are driving significant momentum as we build a dedicated precision cardiology company," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "This quarter, we advanced our lead development programs, ATR 1072 and ATR 1086, while establishing the strategic and operational foundation required to pioneer RNA therapeutics in the precision cardiology space. With a clear strategy, a well-characterized RNA delivery platform and a deep commitment to patients, we believe we are well-positioned to advance therapies for people living with genetic cardiomyopathies who have limited or no therapeutic options."","length":720,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Launched as an independent, publicly traded precision cardiology com...